Detection of the Mr 110,000 Lung Resistance-related Protein LRP/MVP with Monoclonal AntibodiesAnouk B. Schroeijersa, George L. Scheffera, Anneke W. Reursa, Adriana C.L.M. Pijnenborga, Ciro Abbondanzab, Erik A.C. Wiemerc, and Rik J. Scheperaa Department of Pathology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands b Instituto di Patologia Generale ed Oncologia, Seconda Università Degli Studi di Napoli, Napoli, Italy c Institute for Hematology, Erasmus University Rotterdam, Rotterdam, The Netherlands Correspondence to: Rik J. Scheper, Academic Hospital Vrije Universiteit, Dept. of Pathology, PO Box 7057, 1007 MB Amsterdam, The Netherlands. E-mail: rj.scheper@vumc.nl The Mr 110,000 lung resistance-related protein (LRP), also termed the major vault protein (MVP), constitutes >70% of subcellular ribonucleoprotein particles called vaults. Overexpression of LRP/MVP and vaults has been linked directly to MDR in cancer cells. Clinically, LRP/MVP expression can be of value to predict response to chemotherapy and prognosis. Monoclonal antibodies (MAbs) against LRP/MVP have played a critical role in determining the relevance of this protein in clinical drug resistance. We compared the applicability of the previously described MAbs LRP-56, LMR-5, LRP, 1027, 1032, and newly isolated MAbs MVP-9, MVP-16, MVP-18, and MVP-37 for the immunodetection of LRP/MVP by immunoblotting analysis and by immunocyto- and histochemistry. The availability of a broader panel of reagents for the specific and sensitive immunodetection of LRP/MVP should greatly facilitate biological and clinical studies of vault-related MDR. (J Histochem Cytochem 49:13791385, 2001) Key Words: lung resistance-related protein, (LRP), major vault protein (MVP), vault, multidrug resistance (MDR), monoclonal antibody (MAb)
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||